N/A N=983 Safety Assessment of Angioplasty Procedures
Angiospastic; Disorder
Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=200 Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina
Stable Angina
Primary: Exercise Time on Treadmill — 28.4; 11.8 seconds
N/A N=93 AngioSculpt® Coronary Bifurcation Study
Coronary Artery Disease · Myocardial Ischemia
Primary: Procedural Success — 91.4 percentage of participants
N/A N=60 Rotational Atherectomy Combined With Cutting Balloon to Optimize Stent Expansion in Calcified Lesions
Coronary Artery Disease · Atherosclerosis
Primary: Minimum Stent Area After Percutaneous Coronary Intervention — 6.7; 6.9 mm^2
N/A N=300 Pivotal Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon
Peripheral Arterial Disease
Primary: Patency at 12 Month Post-procedure — 53; 135 Participants
N/A N=20 Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Device Technical Success — 29 lesions
N/A N=112 Cutting Balloon Study
Pulmonary Artery Stenosis
Primary: Acute Change in Minimum Lumen Diameter Immediately Post-intervention — 85.1; 52.4 percentage change
Phase 3 N=252 Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis
Peripheral Arterial Disease
Primary: Freedom From Target Lesion Revascularization (TLR) — 123; 43 # of participants free from TLR
N/A N=160 Novel Angioplasty Using Coronary Accessor
Patency of the Radial Artery
Primary: Number of Patients With Radial Artery Occlusion — 3; 0 Participants
N/A N=301 Balloon Pump Assisted Coronary Intervention Study
Coronary Artery Disease · Left Ventricular Dysfunction
Primary: Major Adverse Cardiac and Cerebrovascular Events — 23; 24 Participants
N/A N=44 Atherectomy By Laser Ablation With Turbo-Elite
Peripheral Arterial Disease · Peripheral Vascular Disease
Primary: Primary Efficacy Endpoint - Mean Reduction in Percent Stenosis — 39 Participants
N/A N=86 Wall Shear Stress and Neointimal Healing Following PCI in Angulated Coronary Vessels
Coronary Artery Disease
Primary: In Stent Mean Cross-sectional Area of Neo-intimal Tissue Coverage — 1.381; 0.949 mm^2
Phase 2 N=41 PERVIDEO I Registry, The Lutonix Paclitaxel-Coated Balloon Catheter for the Treatment of Coronary In-Stent Restenosis
In-Stent Restenosis
Primary: Percent Diameter Stenosis (%DS) in the Analysis Segment — 36.0 Percentage stenosis of vessel diameter
N/A N=51 Sprinter Legend Balloon Catheter
Coronary Artery Disease
Primary: Procedural Success — 100 Percent of Participants
N/A N=358 Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia
Critical Lower Limb Ischemia
Primary: Late Lumen Loss (LLL) of the Target Lesion by Quantitative Vascular Angiography (QVA) — 0.605; 0.616 mm
N/A N=20 Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease II
Peripheral Arterial Disease
Primary: Clinical Success — 20 Participants
N/A N=75 FLEX Vessel Prep Prior to Angioplasty in Native Arteriovenous Fistulae (AVF)
Arteriovenous Fistula Stenosis
Primary: Primary Safety Endpoint: Serious Adverse Event Rate — 0; 2.7 percentage of patients
N/A N=532 Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Femoropopliteal Arteries
Femoral Artery Stenosis · Popliteal Artery Stenosis · Femoral Artery Occlusion
Primary: Percentage of Participants With Composite Freedom From All-Cause Peri-Operative (≤30 Day) Death and Freedom From Index Limb Amputation, Index Limb Re-Intervention, and…
N/A N=150 Randomized Trial of IN.PACT Admiral® Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease
Peripheral Arterial Disease (PAD)
Primary: Primary Patency — 82.2; 52.4 Percentage of participants — p=<0.001
N/A N=300 Electrophysiological Effects of Late PCI After MI
Cardiovascular Diseases · Heart Diseases · Myocardial Infarction
Primary: Short-termed Fractal Scaling Exponent (Alpha 1) — 0.01; -0.03 unit-less — p=0.34
N/A N=51 PCI Alternative Using Sustained Exercise
Cardiovascular Disease
Primary: Myocardial Perfusion Reserve — 2.76; 2.47; 2.82; 2.52 Ratio
N/A N=163 The Asahi Intecc PTCA Chronic Total Occlusion Study
Coronary Artery Disease · Coronary Artery Chronic Total Occlusion
Primary: Procedure Success — 119 Participants
Phase 4 N=208 Thromboaspiration in Patients With High Thrombotic Burden Undergoing Primary Percutaneous Coronary Intervention (PCI)
Primary PCI for STEMI
Primary: Rate of Complete ST-segment Elevation Resolution at 60 Minutes After the End of the Procedure — 38; 58 Participants
Phase 2 N=101 LEVANT I, The Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis
Atherosclerosis · Vascular Disease · Arteriosclerosis
Primary: Angiographic Late Lumen Loss — 0.46; 1.09 mm — p=0.016
N/A N=112 Evaluation of the FreedomFlow™ Orbital Atherectomy System to Treat Peripheral Artery Disease
Peripheral Arterial Disease
Primary: Technical Success — 144 lesion
N/A N=50 Pulmonary Artery Repair With Covered Stents
Pulmonary Stenosis · Pulmonary Regurgitation · Tetralogy of Fallot
Primary: Successful Repair of Conduit Disruption — 48 participants
N/A N=81 Paclitaxel Releasing Balloon in Patients Presenting With In-Stent Restenosis
In-stent Coronary Artery Restenosis
Primary: In-stent Late Lumen Loss — 0.07 mm
N/A N=37 Disrupt PAD+ Study With the Shockwave Medical M5+ Peripheral IVL System
Peripheral Arterial Disease · Vascular Disease, Peripheral
Primary: Number of Participants With Major Adverse Events (MAE) — 0 Participants
N/A N=29 JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions
Restenosis · Peripheral Vascular Disease
Primary: Acute Procedural Success — 29 limbs
N/A N=227 Pivotal Study for the FLAIR Endovascular Stent Graft
Stenoses
Primary: Percent of Participants With Treatment Area Primary Patency (TAPP) — 51; 23; 60 Percentage of Participants — p=<0.001